Shares Magazine
0.53p-0.01 (-1.62%)19 Nov 2024, 11:14
Jump to:
Theracryf PLC Fundamentals
| Company Name | Theracryf PLC | Last Updated | 2024-11-19 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 427.347 m | Market Cap | £2.21 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.3080 | Cash Equity Ratio | 0.8560 |
| Quick Ratio | 3.4592 | Current Ratio | 4.19 |
| Price To Book Value | 0.9584 | ROCE | 0 |
Theracryf PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Theracryf PLC Company Financials
| Assets | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tangible Assets | 0 | £3,000.00 | £5,000.00 | £5,000.00 |
| Intangible Assets | £34,000.00 | £43,000.00 | £53,000.00 | £66,000.00 |
| Investments | 0 | 0 | 0 | 0 |
| Total Fixed Assets | £35,000.00 | £46,000.00 | £58,000.00 | £71,000.00 |
| Stocks | 0 | 0 | 0 | 0 |
| Debtors | £497,000.00 | £43,000.00 | £13,000.00 | £16,000.00 |
| Cash & Equivalents | £2.00 m | £5.00 m | £9.03 m | £11.59 m |
| Other Assets | £1,000.00 | 0 | 0 | 0 |
| Total Assets | £3.06 m | £6.17 m | £9.64 m | £12.42 m |
| Liabilities | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Creditors within 1 year | £723,000.00 | £833,000.00 | £411,000.00 | £607,000.00 |
| Creditors after 1 year | -£2,000.00 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | £721,000.00 | £833,000.00 | £411,000.00 | £607,000.00 |
| Net assets | £2.34 m | £5.34 m | £9.23 m | £11.81 m |
| Equity | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Called up share capital | £687,000.00 | £687,000.00 | £687,000.00 | £687,000.00 |
| Share Premium | £27.87 m | £27.87 m | £27.87 m | £27.87 m |
| Profit / Loss | -£3.57 m | -£5.01 m | -£3.17 m | -£3.21 m |
| Other Equity | £2.34 m | £5.34 m | £9.23 m | £11.81 m |
| Preference & Minorities | 0 | 0 | 0 | 0 |
| Total Capital Employed | £2.34 m | £5.34 m | £9.23 m | £11.81 m |
| Ratios | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 | 0 |
| Assets / Equity | 1.3080 | 1.3080 | 1.3080 | 1.3080 |
| Cash / Equity | 0.8560 | 0.8560 | 0.8560 | 0.8560 |
| EPS | -£0.01 | -£0.01 | -£0.01 | -£0.02 |
| Cash Flow | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash from operating activities | -£3.00 m | -£4.13 m | -£2.58 m | -£2.93 m |
| Cashflow before financing | 0 | 0 | 0 | £7.47 m |
| Increase in Cash | -£3.00 m | £490,000.00 | -£1.08 m | £1.46 m |
| Income | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Turnover | £396,000.00 | £442,000.00 | 0 | £194,000.00 |
| Cost of sales | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Profit | -£3.57 m | -£5.10 m | -£3.19 m | -£3.21 m |
| Pre-Tax profit | -£3.57 m | -£5.01 m | -£3.17 m | -£3.21 m |
Theracryf PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases. |
| Latest Interim Date | 28 Nov 2024 |
| Latest Fiscal Year End Date | 28 May 2024 |
Theracryf PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-08-29 | Dr. Huw Jones | Executive Director,Chief Executive Officer |
| 2024-04-05 | Dr. Susan Elizabeth Foden | Non-Executive Director,Chairman |
| 2017-06-23 | Mr. John Bradshaw | Executive Director,Finance Director and Company Secretary |
| 2020-04-30 | Dr. Stephen Joseph Franklin | Executive Director,Chief Executive Officer |
| 2024-05-30 | Mr. Richard Anthony Moulson | Executive Director,Chief Financial Officer |
| 2017-04-03 | Dr. Mark Andrew Wyatt | Non-Executive Director |
| 2023-09-05 | Mr. Barry Clare | Executive Director,Chairman |
| 2018-11-08 | Dr. Marc Francois d’Abbadie | Non-Executive Director |
| 2024-05-30 | Dr. Alan John Barge | Non-Executive Director,Senior Independent Director |
| 2023-12-28 | Ms. Susan Elizabeth Clement-Davies | Non-Executive Director |
| 2024-08-29 | Mr. Toni Markus Antero Hanninen | Executive Director,Chief Financial Officer |
Theracryf PLC Contact Details
| Company Name | TheraCryf PLC |
|---|---|
| Address | Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, L3 5RF |
| Telephone | |
| Website | https://www.evgen.com |
Theracryf PLC Advisors
| Auditor | RSM UK Audit LLP |
|---|---|
| Phone | +44 1516002600 |
| Remuneration Consultant | PricewaterhouseCoopers LLP |
|---|---|
| Phone | +44 205835000 |
| Fax | +44 208224652 |
| Stockbroker | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Registrar | S.L.C Registrars Ltd |
|---|---|
| Phone | +44 1903706150 |
| Nominated Adviser | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Financial PR Adviser | Buchanan |
|---|---|
| Phone | +44 2074665000 |
| Fax | +44 2074665001 |
| Solicitor | Pinsent Masons LLP |
|---|---|
| Phone | +44 2074187000 |
| Fax | +44 2074187050 |
| Solicitor | Theobald Associates |
|---|---|
| Phone | +44 2073978434 |
| Fax | +44 2073978400 |
| Stockbroker | Stockdale Securities Ltd |
|---|---|
| Phone | +44 2076016100 |
| Nominated Adviser | Stockdale Securities Ltd |
|---|---|
| Phone | +44 2076016100 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Bodycote PLC | 621.00 | 8.00 |
| Petershill Partners PLC | 256.00 | 6.22 |
| Hochschild Mining PLC | 228.50 | 5.54 |
| Vesuvius PLC | 387.02 | 4.74 |
| Crest Nicholson Holdings PLC | 153.30 | 4.00 |
| The Renewables Infrastructure Group Limited | 92.70 | 3.58 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Diploma PLC | 4,174.00 | -7.98 |
| Burberry Group PLC | 863.00 | -4.66 |
| Ceres Power Holdings PLC | 168.00 | -3.50 |
| Close Brothers Group PLC | 200.00 | -3.10 |
| Melrose Industries PLC | 510.63 | -3.03 |
| Senior PLC | 143.20 | -2.98 |